Clincosm LogoSign in Get a demo

hypoglycemic agents

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,

Recruiting
  • Glucose Metabolism Disorders
  • +3 more
  • Empagliflozin 10 MG
  • Insulin+Metformin+DPP4 inhibitor (DPP4I)
  • Karachi, Pakistan
    SINA Shireen Jinnah colony
Nov 28, 2023

Diabetes, Diabetes, Type 2, Glucose Metabolism Disorders Trial in Japan (Dulaglutide, Biguanide (BG), Sulfonylurea (SU))

Active, not recruiting
  • Diabetes Mellitus
  • +6 more
  • Nagoya-shi, Aichi, Japan
  • +43 more
Jan 16, 2023

COVID 19, Coronavirus, Diabetes, Type 2 Trial in Be'er Ya'aqov, Petah tikva (Linagliptin 5 MG)

Terminated
  • COVID 19
  • +14 more
  • Linagliptin 5 MG
  • Be'er Ya'aqov, Israel
  • +2 more
May 28, 2021

Resistance Training, Sport Performance, Muscle Recovery Trial in Porto Alegre (Resistance Training)

Unknown status
  • Resistance Training
  • +4 more
  • Resistance Training
  • Porto Alegre, Rio Grande Do Sul, Brazil
    Fundação Universitária de Cardiologia/ Instituto de Cardiologia
Jun 20, 2020

Vascular Stiffness, Hypoglycemic Agents, Diabetes Complications Trial in Ljubljana (Empagliflozin 25mg, Metformin,

Unknown status
  • Vascular Stiffness
  • +3 more
  • Empagliflozin 25mg
  • +3 more
  • Ljubljana, Slovenia
    University Medical Centre Ljubljana
Aug 18, 2018

Diabetes, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring Trial in Porto Alegre (MET + Vildagliptin Group, MET +

Unknown status
  • Diabetes Mellitus, Type 2
  • +3 more
  • MET + Vildagliptin Group
  • MET + Glibenclamide Group
  • Porto Alegre, Rio Grande do Sul, Brazil
    Hospital de Clínicas de Porto Alegre Porto Alegre
May 5, 2014